UNSPSC 51132239: Aspirin/magnesium carbonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132239 Aspirin/magnesium carbonate is a Commodity code that in recent state and local procurement activity covers a much broader range of pharmaceuticals and over-the-counter health products than the code name alone suggests. State and local buyers under this code are procuring generic multi-source pharmaceuticals, naloxone and drug deactivation systems, and OTC products through both individual and cooperative purchasing agreements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Texas Health and Human Services Commission represent recent active buyers in this space.

The code shows activity across Florida, Texas, and the upper Midwest through Minnesota's cooperative purchasing vehicle. Recent opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida (due July 26, 2023); the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon (due March 26, 2026); and the Texas Health and Human Services Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription fulfillment capabilities (posted April 3, 2026). The MMCAP cooperative contract requires vendors to work through three authorized wholesalers, meet cGMP and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee, with contract terms of two years for new vendors and optional extensions. Naloxone procurement appears driven by community health initiatives and opioid-response funding, while pharmaceutical cooperatives emphasize price competitiveness and multi-state scale.